Cambridge, United States
BIORCHESTRA Co., Ltd. is a pioneering biotech company established in 2016, aiming to significantly advance therapeutics through innovative RNA-based solutions. The company is at the forefront of shifting treatment paradigms in the realm of neurodegenerative diseases, moving from symptomatic relief to fundamental cures. Their novel approach holds promise for a transformative impact on the biopharma and biotechnology sectors.
Based in the United States, BIORCHESTRA is actively seeking global partnerships to enhance its research and development efforts and broaden its commercial reach. The firm made notable progress with a KRW54.50B Series C funding round on 22 February 2022.
The investment round drew substantial interest and backing from prominent investors including Smilegate Investment, DAYLI Partners, IMM Investment, LSK Investment, Widwin Investment, Quantum Ventures Korea, SBI Investment Korea, Chong Kun Dang, GS Holdings, and E&Venture Partners. This strong support reaffirms confidence in the company's mission and potential for significant industry impact.
